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Abstract
Cancer is an inflammatory disease of tissue that is largely influenced by the interactions between
multiple cell types, secreted factors, and signal transduction pathways. While single-cell
sequencing continues to refine our understanding of the clonotypic heterogeneity within tumors,
the complex interplay between genetic variations and non-genetic factors ultimately affects
therapeutic outcome. Much has been learned through bulk studies of secreted factors in the tumor
microenvironment, but the secretory behavior of single cells has been largely uncharacterized.
Here we directly profiled the secretions of ELR+ CXC chemokines from thousands of single
colorectal tumor and stromal cells, using an array of subnanoliter wells and a technique called
microengraving to characterize both the rates of secretion of several factors at once and the
numbers of cells secreting each chemokine. The ELR+ CXC chemokines are highly redundant,
pro-angiogenic cytokines that signal via either or both of the CXCR1 and CXCR2 receptors,
exerting profound impacts on tumor growth and progression. We find that human primary
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colorectal tumor and stromal cells exhibit polyfunctional heterogeneity in the combinations and
magnitudes of secretions for these chemokines. In cell lines, we observe similar variance:
phenotypes observed in bulk can be largely absent among the majority of single cells, and
discordances exist between secretory states measured and gene expression for these chemokines
among single cells. Together, these measures suggest secretory states among tumor cells are
complex and can evolve dynamically. Most importantly, this study reveals new insight into the
intratumoral phenotypic heterogeneity of human primary tumors.
Introduction
Tumors comprise a complex, heterogeneous population of cells. Genomic characterization
of tumors has revealed the clonotypic variations evident from mutations, amplifications,
rearrangements, and translocations of oncogenes, among other genetic aspects that promote
tumor growth and survival.1 This genetic variability strongly influences the observed
phenotypic heterogeneity in cancer. Nonetheless, non-genetic factors such as epigenetics
and stochastic variations in the tumor microenvironment also affect the states of cells
present in the tumor.2 For example, dysregulated signaling and inflammation in the
microenvironment can suppress anti-tumor immunity; recruit and reprogram supportive
stromal cells; and promote tumor growth, invasion, angiogenesis, metastasis, and resistance
to treatment.3-6 Both genetic and non-genetic sources of phenotypic heterogeneity can limit
the efficacy of treatments and enable the emergence of resistance.7-9 While genomic
sequencing has begun to refine the clonotypic heterogeneity within tumors,10-13 further
understanding of how functional variations manifest within the tumor microenvironment is
needed to inform new strategies for disrupting the intercellular networks involved in
maintenance of the tumor.
Chemokines and their respective receptors play an important role in mediating intercellular
communication within the tumor microenvironment.14 These factors have been implicated
in the maintenance and robustness of tumor-host interactions, as well as chemotaxis.3-6
Their effects on the growth and progression of the tumor can be both indirect, through
recruitment of pro-inflammatory leukocytes, and direct, through autocrine or paracrine
signaling. The proangiogenic CXC chemokines that bind CXCR1 and CXCR2 have a
common tri-peptide motif—Glu-Leu-Arg (ELR)—preceding a conserved motif of two non-
adjacent cysteines (CXC).15-17 These ELR+ CXC chemokines and their receptors are often
found to be upregulated in tumor relative to normal tissue, and are potential therapeutic
targets.18-25 Both CXCL1 and CXCL5 have been observed to increase in tumors with
progression of colorectal cancer by immunohistochemistry, qPCR, and ELISA using tissue
lysates.26 CXCL8 is also more highly expressed in human colorectal carcinomas than
normal tissue.27 The increased levels of these chemokines suggest they may have a role in
the initiation and transformation of colorectal cancers, but relatively little is known about
how these factors are released into the microenvironment at the single-cell level.
Here, we examined the heterogeneity among the secretory states of cells from colorectal
tumors for CXCL1, CXCL5, and CXCL8. To make these measurements, we used a method
called quantitative microengraving, a technique that assesses the secretion of multiple
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proteins from thousands of single cells in parallel.28-33 Characterizing cells from human
colorectal tumor, stroma, adjacent normal tissue, and a lung metastasis, we find that single
cells exhibit a range of secretory phenotypes for these three chemokines, with various
magnitudes of chemokines released. These varied states of secretion are also evident among
cell lines derived from colorectal tumors. Furthermore, we demonstrate that the
polyfunctional phenotypes inferred from bulk measures obscure the heterogeneity in
responses by single cells, and that the secretory states of individual cells can be discordant
with the expression of transcripts encoding these chemokines. Together, these results
indicate that the secretion of ELR+ CXC chemokines by cells resident in colorectal tumors
is highly heterogeneous and plastic. In view of their known redundancies in binding to a
common receptor (CXCR2), these data suggest that the heterogeneous release of these
chemokines by individual cells promotes a robust, evolving, yet noisy, signaling network
within the tumor microenvironment.
Methods
Clinical samples
Human primary colorectal adenocarcinoma and adjacent normal epithelium were obtained
as discarded samples from Massachusetts General Hospital, as part of the Institutional Board
Review approved protocol 201-P-000632/16.df. Patients were males and females between
the ages of 46 and 79 years old with at least stage III colorectal adenocarcinoma. Normal
epithelium was obtained as a discarded sample from an 18 year-old patient with carcinoma
in situ. A lung metastasis was also obtained as a discarded sample, from a 55 year-old male
with stage IV rectal cancer, from the Lahey Clinic.
Disaggregation of human primary tissue
Roughly 1 cm3 of human primary tissue, transported on ice, was washed with 50 mL of PBS
then diced with No. 10 scalpels (BD Parker) into 1 mm-thick pieces. The slices were
submerged in 1 mL of RPMI media (Cellgro) containing collagenase A (Roche) at 1 mg/mL
and DNAse1 (Roche) at 105 units/mL for 30 min at 37 °C. Then, the solution was put
through a 40 μm cell strainer (BD Parker), centrifuged ×300g for 5 min, and resuspended in
F medium containing the rho-kinase inhibitor Y-27632.34 Cells were loaded into the
nanowells immediately following disaggregation and cultured for 2 days at 37 °C in F
medium with Y-27632, without feeder cells, to promote recovery prior to assaying for
protein secretion. The entire process of disaggregating and loading cells into the nanowells
was completed within roughly 1 h.
Cell culture
SW1222, LIM1215, Colo205, HT29, HCT116, HCT15, LS180, and LS147T colorectal
tumor cell lines were obtained from the American Type Culture Collection (ATCC). The
HCT15 colorectal tumor cell line was the kind gift of Michael S. Goldberg (Dana Farber).
SW1222, LIM1215, Colo205 and HCT15 were maintained in RPMI1640 media (Cellgro)
supplemented with 10% v/v HI-FBS, 100 units/mL penicillin and 100 μg/mL streptomycin
(Cellgro). HT-29, HCT116, LS180, and LS147T were maintained in DMEM media
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(Cellgro) supplemented with 10% v/v HI-FBS, 100 units/mL penicillin and 100 μg/mL
streptomycin.
Quantitative microengraving
Quantitative microengraving was performed, using poly-l-lysine slides coated with capture
antibodies, as previously described.28 Prepared poly-l-lysine slides were coated with an 80
μL mixture of capture antibodies at 25 μg/mL each in a buffer comprising 50 mM sodium
borate, 8 mM sucrose and 50 mM NaCl (pH 9.0), under a lifter slip in a humidity chamber
overnight at 4 °C. The slides were blocked with non-fat milk in PBST (PBS with 0.05%
(v/v) Tween 20) for 30 min and washed 3x with PBST and PBS prior to use. Monoclonal
capture (CXCL1, clone 20326; CXCL5, clone 33170; CXCL8, clone 6217) and polyclonal
detection antibodies were purchased from R&D Systems.
Replica molding with a custom-built mold was used to form a 1 mm-thick
polydimethylsiloxane (PDMS, Dow Corning) array of 72 × 24 blocks, each containing a 7 ×
7 grid of subnanoliter wells (50 μm × 50 μm × 50 μm). Following oxygen plasma treatment
for 2 min, the array was loaded with a cell suspension, washed with growth media, and
sealed with a capture slide in a hybridization chamber (Agilent Technologies, G2534A) for a
set interval of time under normal cell culture conditions. Then, the capture slide was
removed under a bath of media, blocked with 3% non-fat milk in PBST for 30 min,
incubated with a mixture of 1 μg/mL fluorescent detection antibodies for 45 min, washed
with PBST and PBS, and dried with N2 compressed gas.
The slide was imaged on a Genepix 4200AL microarray scanner and analyzed using the
accompanying software (GenePix 7, MDS Corp). This software was used to quantify
fluorescence intensities and score positive events as having median fluorescence intensities
greater than the median plus two standard deviations of wells with negative signals. Features
with saturated pixels (> 1%) or low signal-to-noise ratio (< 1) were removed for quality
control. Standard curves were formed by spotting detection antibodies diluted in water onto
poly-l-lysine slides (1 μL per spot) in a dilution series, drying under vacuum, and scanning
on the Genepix 4200AL (Fig. S1). These standard curves were used to convert the
fluorescence intensities corresponding to specific numbers of molecules of detection
antibody present per 50 × 50 μm feature, assuming a 1:1 stoichiometric ratio between
detection antibody and analyte in the dilute limit for the quantity of analyte.28 Reference
curves for microengraving were prepared with each lot of reagents, and verified for
consistency with each measurement performed. The lower limit of detection for quantitative
microengraving was assessed from the presence of a signal greater than the background plus
two standard deviations, and related to the number of molecules from our standard curves.
GraphPad PRISM software was used to perform the Mann-Whitney test on measured
secretion rates and the Chi-Square and unpaired t-tests on frequencies of secretions. A
schematic of the workflow is shown in Fig. S2.
Image cytometry
Cells on the PDMS array were stained with 4 μM calcein violet (Invitrogen), 1 μM SYTOX
green nucleic acid stain (Invitrogen), one test of anti-human CD326 PerCp-eFluor710
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(eBioscience), and one test of anti-human CD45 AlexaFluor 647 (Biolegend), in 250 μL of
growth media under a lifter slip for 1 h. Imaging of the array was performed on an
automated epifluorescence microscope (Zeiss) and cells in the nanowells were enumerated
using a custom software program (Enumerator; available for academic use upon request).
Immunophenotyping was performed after secretion measurements were obtained, so any
cells that were lost from the nanowells after microengraving would have been neglected
from the analysis. Only wells with one cell were included in the analysis.
qRT-PCR
qRT-PCR was performed using TaqMan One-Step RT-PCR Master Mix (Invitrogen) and
TaqMan gene expression assays for CXCL1, 5, 8, CXCR1, 2, ActB, and GAPDH
(Invitrogen), on a Roche LightCycler 480II. Ct values were obtained using the second
derivative method, and data were normalized to GAPDH using the delta-delta-Ct method.
Single-cell retrieval and qRT-PCR
Single cells were classified by secretory phenotype using microengraving. The arrays
containing the cells were treated for 15 min with 0.25% trypsin-EDTA (Invitrogen), and
then retrieved from the nanowells by robotic micromanipulation (ALS Aviso
CellCelector).33 Lysis and reverse transcription of single cells was performed using the
Ambion Single Cell-to-CT Kit (Invitrogen). TaqMan Gene Expression Assays (Invitrogen)
were used with 40 cycles of PCR on the Fluidigm Biomark with TaqMan GTXpress Master
Mix (Invitrogen). Data are presented in terms of threshold expression (Et), defined by 40 -
Ct.35
Protein microarrays
A fluorescent-based, sandwich-style assay was used to estimate the quantity of secreted
chemokines from different human colorectal tumor cell lines. Briefly, monoclonal
antibodies for capturing secreted human CXCL1, 5, and 8 were diluted in a buffer
comprising 50 mM sodium borate, 8 mM sucrose and 50 mM NaCl (pH 9.0) to a final
concentration of 250 μg/mL and spotted by hand on the surface of poly-L-lysine slides (1
μL/spot) for at least 1 h at 25 °C. Slides were then placed in non-fat milk (3% w/v in PBS,
pH 7.4) for 30 min at 25 °C and washed two times with PBST, dipped in water, and spun
dry. The slides were each placed in 24-well Microplate Microarray Hardware (ArrayIt,
MMH96). A series of each recombinant analyte CXCL1, CXCL5, and CXCL8 (R&D
Systems), serially diluted in DMEM media from 0.01 to 100 ng/mL, were added to the wells
(100 μL of solution per well) in order to generate standard curves (Fig. S1). In parallel, 100
μL of bulk supernatants from cell cultures were added to other wells of these partitioned
slides. After incubating for 1 hr at 37 °C, the excess media containing unbound protein was
removed, and each well was washed twice with PBST (2×250 μL). Then, the slide was
placed on a Tecan HS 400 Pro Hybridization Station at 25 °C for incubation with 1 μg/mL
of the following polyclonal detection antibodies in PBST: anti-CXCL1 labeled with
Alexa488, anti-CXCL5 labeled with Alexa647, and anti-CXCL8 labeled with Alexa594.
The labeled microarray slides were then scanned using a Genepix 4200AL microarray
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scanner (Molecular Devices) in order to quantify fluorescence intensities, generate standard
curves for analyte standards, and calculate concentrations of the bulk culture supernatant.
Results
Single cells from human tumor and normal tissue secrete ELR+ CXC chemokines
heterogeneously
To measure directly the secretory behavior of single cells from human tumor and normal
tissue, we performed quantitative microengraving for CXCL1, 5, and 8, then
immunophenotyped the same cells via on-chip cytometry for CD45 and EpCAM (Fig. 1a).
Cells found to be secreting versus non-secreting exhibited detectable versus undetectable
levels of secretion, respectively, within the limits of detection of our assay. Small
percentages of both individual tumor cells (EpCAM+; 0.1-1.2%) and leukocytes (CD45+;
1.3-3.6%) secreted quantities of CXCL1, 5, and 8 over 4 h that were greater than the limits
of detection for each analyte measured (approximately 0.1 molecules/s) (Fig. 1b, Fig. S1).
The combinations of secreted chemokines measured for these cells varied from single
analytes (CXCL1, 5, or 8 only) to all other discrete combinations. There was no consistent
difference between the percentages of populations of tumor cells and leukocytes isolated
from the tumors that secreted detectable quantities. We repeated the measurements four days
later and different distributions of secretory phenotypes were observed (Fig. S3), suggesting
that the secretory states of tumor cells are not fixed and are sensitive to their environmental
conditions.
Among the three primary tumors characterized, the median rates of secretion for a given
chemokine did not vary significantly as a function of the specific functional phenotype
observed (CXCL1, 0.3 to 0.9 molecules/s; CXCL5, 0.6 to 3.1 molecules/s; CXCL8, 1.9 to
4.8 molecules/s) (Fig. 1c). This indifference of individual cells to their own secretory state
suggests that there are little, if any, additive autocrine effects among these three chemokines.
We note that the ranges of rates are also similar to those previously reported for cytokines
secreted from human primary cells so it is also possible that their release is constrained by
the specific secretory capacity of a given cell.28 Further supporting this possible mechanism,
the overall median rates for all three chemokines did not differ significantly between tumor
cells and leukocytes. Together, these results suggest that single tumor cells can exhibit
diverse and independent secretory profiles from one another and that these profiles can
evolve in a dynamic manner.
We then compared the secretory phenotypes of single cells isolated from other tissues,
including a lung metastasis, two normal colon samples, and one normal ileum epithelium.
Individual cells from these samples also exhibited diverse secretory profiles for CXCL1, 5
and 8 (Fig. 2a). Similar to cells from primary tumors, there were few epithelial cells or
leukocytes secreting detectable quantities over 4 h. For two of the three normal samples, a
higher percentage of leukocytes secreted chemokines than EpCAM+ epithelial cells (normal
colon #1, p<0.005; and normal ileum, p<0.0001). Median secretion rates of CXCL1, 5, and
8 among secreting cells were also of similar magnitude between cells from both tumor and
normal samples (Fig. 2b) with statistically-significant differences in CXCL1 for EpCAM+
and CD45+ cells, and in CXCL8 for EpCAM+ cells. The percentage of EpCAM+ cells
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isolated from tumors secreting detectable quantities of chemokines (0.49%) was slightly
greater than those cells (0.13%) from normal tissue; the percentage of secreting CD45+ cells
from the primary tumors (2.2%) was comparable to that from normal tissue (2.0%) (Fig. 2c).
Neither of these differences was statistically significant. Previous reports have demonstrated
that CXC chemokines are overexpressed in tumor microenvironments in bulk relative to
normal tissues when measured by qPCR or ELISA from tissue lysates or intracellular
staining by immunohistochemistry.26,27 Our data suggest that the detectable secretion of
these chemokines may be regulated and that cells from the tumor may not have substantially
enhanced capacities for secretion.
Colon tumor cell lines express mRNA for ELR+ CXC chemokines and receptors and
secrete these chemokines in bulk
The polyfunctional diversity in secretory states observed among the heterogeneous
populations of cells isolated from primary tumors led us to further characterize whether
colon cancer cell lines might also exhibit a breadth of secretory states for ELR+ CXC
chemokines. CXCL1 and CXCL5 signal exclusively via CXCR2, but CXCL8 signals via
both CXCR1 and CXCR2. We therefore performed gene expression analysis for CXCL1,
CXCL5, and CXCL8, and the chemokine receptors, CXCR1 and CXCR2 for each of eight
cell lines (Fig. 3a). Five of the eight cell lines expressed transcripts for the three
chemokines; HCT116, LS147T, and Colo205 did not express CXCL5. The fractional
quantities of each gene varied among cell lines, however—for example, HT29, LS180, and
SW1222 were near the limit of detection for CXCL5. All of the cell lines expressed similar
quantities of transcripts for both chemokine receptors. These data together show that five of
the eight cell lines considered here can express the three chemokines, and that they all have
the capacity to produce receptors for them.
We then measured the bulk quantities of CXCL1, 5, and 8 present in the supernatants
collected from the same cell lines by quantitative protein microarrays (Fig. 3b). The amounts
of CXCL8 correlated well with the amounts of expressed mRNA, while CXCL1 was not
correlated with the gene expression across the eight lines (Fig. 3c). Only the two lines with
highest amounts of CXCL5 mRNA—HCT15 and LIM1215—had detectable quantities of
CXCL5. In sum, these data indicate that each of the eight cell lines is capable of producing
at least two of the three chemokines.
Single cells from colon tumor cell lines also exhibit heterogeneous secretions of ELR+
CXC chemokines
We then chose three cell lines—HCT15, HT29, and LIM1215—that each exhibited bulk
production of two or three chemokines to study more extensively, at the single-cell level.
Secretions of CXCL1, 5, and 8 from individual cells from each cell line were characterized
by quantitative microengraving (Fig. 4a). Interestingly, most secreting cells did not exhibit
the functional phenotypes inferred from the bulk measures for each line. For example, both
CXCL1 and CXCL8 were evident in the supernatants from the HT29 cell line, but only
5.5% of HT29s secreted detectable quantities of both CXCL1 and CXCL8 simultaneously.
The majority of HT29s secreting detectable quantities of chemokines released CXCL8 only
(86.2%), while the remaining secreted CXCL1 only (8.3%). Similarly, HCT15s and
Adalsteinsson et al. Page 7













LIM1215s had measureable amounts of all three chemokines in bulk, but individual cells
secreting detectable quantities of all three chemokines concurrently were rare among the
HCT15s (0.3%) and LIM1215s (0.9%). There was also variation among the measured rates
of secretion for single cells in the three tumor cell lines (Fig. 4b). These data suggest that the
breadth of secretory states for chemokines can vary at the single-cell level, even among cell
lines, and that the pro-inflammatory milieu in a tumor microenvironment may develop from
a combination of discrete single-cell behaviors reflecting complex phenotypes not evident
from bulk measures.
Given that the bulk gene expression data for these lines showed all three genes expressed in
these lines but the individual cells showed variances in their dominant secretions, we then
evaluated the mRNA expression of CXCL1, 5, 8, and CXCR1 and 2, in both single HT29
cells secreting detectable quantities of CXCL8 only and those not secreting detectable
amounts of any of the three chemokines (CXCL1, 5, or 8) (Fig. 4c). Both phenotypes
showed varying levels of CXCL1, 5, 8, and CXCR1 and 2 mRNA, with many cells
expressing transcripts for analytes not detected. Though the measures of single-cell secretion
are constrained by the lower limit of detection of the assays here, these data suggest that
there is discordance between the gene expression of these chemokines and the dominant
secretory state of the cells over a given interval in time. This discordance also further
supports a model wherein secretory states may evolve dynamically in their local
environments.
Other secreted factors in the tumor microenvironment are heterogeneous
The diversity among the functional phenotypes observed for single cells producing
chemokines suggested that such heterogeneity might also apply to other secreted factors
commonly measured from tumors or the constituent cells. To expand our study of the tumor
microenvironment, we developed a panel of antibodies to detect 26 different secreted factors
previously reported from bulk analyses of primary tumors and cell lines (Fig. S4). These
analytes included chemokines (CCL2, CCL5, CXCL8, CXCL12), interleukins (IL-2, IL-4,
IL-5, IL-6, IL-7, IL-10, IL-13, IL-17A), monokines (IL-1β, TNF), a matrix metalloprotease
(MMP9), and the following growth factors: transforming (TGF-β1, BMP-2, BMP-6),
hematopoietic cell (M-CSF, GM-CSF), epidermal (EGF), hepatocyte (HGF), platelet-
derived (PDGF-BB), nerve (BDNF, beta-NGF), and vascular endothelial (VEGF). We found
that the viable cells isolated from six human primary colorectal tumors exhibited a broad
diversity in their individual secretory signatures (Fig. S5). Interestingly, single-cell
secretions of CXCL8 and MMP9 were the two most common factors observed among these
samples (CXCL1 and CXCL5 were not screened in this panel). MMP9 is a matrix
metalloprotease that degrades extracellular matrix and facilitates tumor cell invasion. MMP9
is reportedly overexpressed in tumor relative to normal tissue and expression has been
associated with poorer prognosis in colorectal cancer.36 These data further emphasize the
dynamic complexity of the tumor microenvironment as evidenced by the diverse operational
states exhibited by individual cells comprising the tumor.
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The tumor microenvironment comprises a complex network of cells and proteins that
facilitate the maintenance and survival of the tumor. In this paper, we directly profiled the
secretory behavior of individual tumor, stromal, and adjacent epithelial cells, using
quantitative microengraving over short time scales (2-4 h) with a resolution not common in
cancer research. Characterization of tumors using bulk, integrated measures such as ELISA
and qPCR have identified many secreted factors and genes for secreted factors that are
constitutively present in the microenvironment or arise from perturbations (e.g., treatment
with drugs) to the microenvironment. Our single-cell analysis here reveals, however, that
individual cells can contribute to this inflammatory milieu using a complex set of functional
phenotypes. We find that the phenotypic state suggested by a bulk measure does not
accurately reflect the states of the individual cells contributing to the overall milieu (Fig.
S6). This insight emphasizes that bulk measures can reflect average states discordant from
those at the single-cell level and obscure rare operational behaviors of single cells by their
intrinsic reduction of spatiotemporal dimensionality.7
We demonstrate that single cells isolated from human primary tumors and tumor cell lines
can exhibit a variety of secretory states at any given instance, and show that these
phenotypic states of secretion can evolve. Indeed, only a small percentage of cells secrete
detectable quantities of chemokines over short time intervals (2-4 h). These single-cell
behaviors suggest that small fractions of highly active cells, acting with different functional
phenotypes, could contribute to alter the tumor microenvironment dynamically (Fig. 5). In
this model, the robustness and redundancy of intercellular signaling via the ELR+ CXC
chemokines can be appreciated—especially since CXCL1, 5, and 8 all have similar EC50’s
for CXCR2.37 Interestingly, similar secretory behaviors were also present among single
cells of normal tissue. Therefore, an increased frequency of highly active secreting cells
within the tumor, driven by autocrine and paracrine signaling—rather than the increased
magnitude of production by any individual cell—could promote elevated levels and may
support tumor progression via positive feedback.
We examined here the heterogeneity and polyfunctionality in secretions of three ELR+ CXC
chemokines, but there are four others (CXCL2, 3, 6, and 7) not included in this study. These
additional factors likely compound the phenotypic heterogeneity observed here further.
While there are opportunities to therapeutically modulate these networks, our data suggest
that such targets are complex and may require approaches that target all possible phenotypic
states within the tumor microenvironment. It also suggests that therapeutics that target
common receptors such as CXCR1 or CXCR2 may be more effective than those targeting
one of the pleotropic chemokines (e.g., CXCL8). For instance, the knockdown of CXCR2 in
ovarian cancer cells leads to arrested cell cycle in G0-G1, decreased angiogenesis, reduced
secretion of ELR+ CXC chemokines, and increased apoptosis.25
The heterogeneous secretory states observed for isolated single cells from tumors represent
the potential landscape of phenotypes available to both epithelial cells and leukocytes. The
measurements on individual cells here do not account for how they may behave when in
contact with different cells within the tissue. One opportunity for further characterization of
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this perturbation on the states of individual cells is to examine the synergistic or antagonistic
effects of cell-cell interactions on the secretory states or phenotypic behaviors.38 Such
measures should further reveal the dynamic intercellular networks governing
communication within the tumor microenvironment. Also, one implication of the
observations here is that in vitro models that rely on static production of chemokines or
growth factors to maintain gradients may imperfectly reflect the temporal dynamics of such
factors as modulated by stochastic bursts in secretion by cells. From our measurements, a
new understanding of ELR+ CXC chemokine signaling in the tumor microenvironment
begins to emerge, involving temporal and discrete fluctuations among small subsets of
highly active secreting cells.
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Fig. 1. Immunophenotyping and secretion of chemokines by human primary colorectal tumor
cells
(A) Micrographs comprising transmitted light and epifluoresence images of single cells from
a disaggregated tumor measured by microscopy and their secretory state measured by
microengraving. (B) Pie charts of the distribution of secretion states from three human
primary colorectal tumor samples (#1-3) measured two days post surgery. The center of
each pie chart shows the number of observed single-cell secretion events over the total
number of live CD45+ or EpCAM+ single cells, respectively. (C) Scatter plots of rates of
secretion for chemokines released by single, live CD45+ leukocytes and EpCAM+ tumor
cells classified by observed secretory state. Limits of detection for 4 h assays were ~0.1
molecules/s. Color-coded bars indicate the same combinations noted in Fig. 1b. The fraction
of secreting leukocytes detected was higher than the tumor cells in tumor #2 (p<0.0001) and
in tumor #3 (p<0.0001), but no statistically-significant differences were observed for tumor
#1.
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Fig. 2. Secretion of chemokines from other sites of the body
(A) Pie charts of the distributions of secretory states observed from single cells of a lung
metastasis, two normal colon samples, and normal ileum epithelium, measured two days
post surgery. The center of each pie chart depicts the number of single-cell secretion events
over the total number of live single cells. (B) Bargraph of the combined median rates of
secretions of CXCL1, 5, and 8 for EpCAM+ and CD45+ cells from both normal colon and
ileum and human primary colorectal tumors. EpCAM+ cells of normal tissue had higher
median secretion rates of CXCL1 and CXCL8 than those of tumor tissue (p<0.05). CD45+
cells of normal tissue secreted higher median levels of CXCL1 than those of tumor tissue
(p<0.05). Error bars indicate interquartile range. (C) Bargraph of percentages of EpCAM+
and CD45+ cells with measured secretions of CXCL1, 5, and 8. Error bars indicate s.e.m.
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Fig. 3. Bulk mRNA expression and production of chemokines by tumor cell lines
(A) Relative gene expression of bulk mRNA for CXCL1, 5, 8, and their receptors, CXCR1
and 2. Data were measured in triplicate and are normalized across the rows via the delta-
delta CT method using GAPDH as the housekeeping gene. (B) Bargraph of the
concentrations of CXCL1, 5, and 8, measured by quantitative protein microarrays in
triplicate, from the supernatants from cultures of 100,000 cells of each cell line. (C)
Scatterplots of normalized mRNA versus secreted protein for CXCL1, 5, and 8. Calculated
Pearson correlation coefficients are shown.
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Fig. 4. Single-cell production of chemokines by tumor cell lines
(A) Pie charts of the distribution of secretory states observed from single cells of three colon
cancer cell lines assayed for 2 h by microengraving. The center of each pie chart depicts the
number of single-cell secretion events over the total number of live single cells. (B) Scatter
plots of the rates of secretion of chemokines measured for live single cells, and classified
according to secretory state, from the three colon cancer cell lines. Limits of detection for 2
h assays were approximately 0.2 molecules/s. (C) Single-cell gene expression measured by
qRT-PCR for HT29 cells selected based on secretory state following microengraving for 2 h
for CXCL8. Ct values were converted to Et values as described in Methods.35
Adalsteinsson et al. Page 16













Fig. 5. Proposed model for ELR+ CXC chemokine signaling in the tumor microenvironment
A small fraction of leukocytes and tumor cells secrete robustly at any given instance in time
with discrete functional phenotypes that can change with time. The measurements in this
study cannot infer the spatial positioning of the cells in the tumor and positioning shown is
schematic.
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